Bavarian Nordic signs an agreement with UNICEF for one million mpox vaccines

Bavarian Nordic A/S specializes in the development, manufacture and marketing of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are split between product sales (97.8%) and services (2.2%). Net sales are distributed as follows: United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8% ), Switzerland (1.5%) , Sweden (1%), Chile (0.9%), Taiwan (0.8%), United Kingdom (0.6%), Hong Kong (0 .2%), Saudi Arabia ( 0.1%) and others (4.9%).